Day: April 30, 2022

VANCOUVER, British Columbia, April 29, 2022 (GLOBE NEWSWIRE) — Candelaria Mining Corp. (TSX-V: CAND, OTC PINK: CDELF) (the “Company”) announces that pursuant to the Company’s stock option plan and restricted share unit plan (together, the “Plans”), the Company granted today a total of 4,120,000 stock options (“Options”) and 461,677 restricted share units (“RSUs”) to directors, officers, employees and consultants of the Company. Each Option is exercisable into one common share of the Company for period of five years at an exercise price of $0.14 per share. All Options vest as follows: one-third after six months from the grant date, one-third at 12 months from the grant date and one-third at 18 months from the grant date. All RSU’s vest at one year from the grant date. All Options and RSUs are subject to the terms of the Company’s...

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S.ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults. Approximately 16 million children, adolescents, and adults have ADHD in the U.S. While many children with ADHD outgrow...

Company to Host First Quarter 2022 Financial Results Conference Call on June 9 at 8:00 AM ET SHANGHAI, China, April 29, 2022 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it has updated its net revenues guidance for the first quarter of 2022 and provided an update on the Company’s recent developments. With macro-economic disruption caused by the unexpected Covid-19 resurgence nationwide in China, and the increased Covid-19 restrictions and lockdowns in major cities including Shanghai since mid-March, the Company currently expects net revenues for the first quarter of 2022 to be in the range of RMB5.0 billion to RMB5.1 billion. This compares with the range of RMB5.3 billion to RMB5.5...